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Abstract
The results of the NICE-SUGAR (Normoglycaemia in Intensive
Care Evaluation Survival Using Glucose Algorithm Regulation) trial
were released last March. The primary outcome variable, 90-day
mortality, was actually increased in patients randomly assigned to
intensive insulin therapy, as compared with an intermediate target
range for blood glucose. These findings, reflecting data collected
in a set of more than 6,000 patients, clearly refute the external
validity of tight glucose control. Future research will probably focus
on several questions raised by the divergent results reported from
investigations in the field of glucose control in the critically ill.
On Tuesday, 24 March 2009 at 10:05 hours, the Erasmus
Room of the Exhibition and Congress Centre of Brussels was
overcrowded. Attendees from all over the world had gathered
for a well planned and widely announced event. Professor
Simon Finfer, from the Royal North Shore Hospital of Sydney,
Australia was about to release the results of the NICE-
SUGAR (Normoglycaemia in Intensive Care Evaluation
Survival Using Glucose Algorithm Regulation) trial, the largest
clinical study conducted in critical care medicine to date. At
the end of his presentation, the article was published and
available on the website of the New England Journal of
Medicine [1].
NICE-SUGAR was designed to test whether tight glucose
control by intensive insulin therapy (TGCIIT; n = 3,010 evalu-
able patients) increases 90-day survival as compared with
less strict glucose control (n = 3,012 evaluable patients). The
issue of TGCIIT has been among the most popular and
passionate areas of debate and discussion since 2001, when
the landmark Leuven I study [2] was published. Several
investigators [3-6] and the Leuven medical ICU team [7] had
already assessed the effects of TGCIIT in various settings
and conditions. These trials failed to reproduce the impres-
sive improvement in survival reported in the Leuven I study
[2]. It is unsurprising (in view of the now presented NICE-
SUGAR findings) that two recent meta-analyses [8,9]
concluded simply that tight glucose control is not associated
with significantly reduced hospital mortality. Criticisms of
each of the individual studies were raised, including inade-
quate statistical power and the use of various degrees of
glucose control, all lower in the subsequent trials [3-7] than in
the initial Leuven I study [2]. Therefore, the NICE-SUGAR trial
was eagerly awaited by the intensive care medicine
community worldwide.
The sample size of NICE-SUGAR was calculated to detect a
3.8% absolute difference in mortality (treatment effect repor-
ted in the Leuven I trial) with a power of 90%, assuming a
baseline mortality of 30% [2]. NICE-SUGAR was conducted
in a network of intensive care units that had previously
collaborated and included patients in large-scale trials. A
web-based electronic algorithm was used to adapt the insulin
infusion rate. Under these conditions (optimal for successful
performance of a multicentre trial) the primary outcome
variable, namely 90-day mortality, was found to be increased
from 24.9% in the conventional/control group arm to 27.5%
in the intensive treatment arm, which is in complete contrast
to the findings of the Leuven I trial. These findings allow us to
address certain issues and provide some answers, but they
also raise new questions.
The main issue considered by NICE-SUGAR - whether the
Leuven I trial has external validity - is clearly addressed in the
negative, in contrast to previous hopes and beliefs. Possible
reasons for the lack of external validity are multiple and
include major differences in the amount of intravenous
glucose infused, the frequency of use of enteral nutrition and
possibly a lower ‘commitment’ to TGCIIT by centres other
than Leuven. Nonetheless, NICE-SUGAR probably succeed-
ed in separating the levels of glycaemia reached in the two
experimental groups, even though the interquartile ranges of
the values are not stated in the report [2]. Whatever the
reason for the disparity between the results of the Leuven I
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trial and other studies, some standards of care will be
changed. The Endocrine Society has already issued a
statement [10], just after the publication of the results of
NICE-SUGAR, advocating the need for more nuanced
recommendations on glucose control. Likewise, other official
bodies (for instance, the Joint Commission on Accreditation
of Healthcare Organizations, the Institute for Healthcare
Improvement and the Volunteer Hospital Organization) that
issued recommendations on tight glucose control in critically
ill patients will need to re-consider their position.
The new questions raised by NICE-SUGAR probably include
the actual validity of the concept of 80 to 110 mg/dl (4.4 to
6.1 mmol/l) as ‘normoglycaemia’ or even desirable glycaemia
during critical illness [11]. Another key but unresolved and
poorly investigated issue is the possible nonglycaemic effects
of insulin in the late divergence in the cumulative survival
curves observed both in the Leuven studies [2,7] and in
NICE-SUGAR [1], albeit in opposite directions. Other
pending questions raised include the risks and potentially
harmful effects of high variability in glucose levels, which are
probably influenced by TGCIIT [12-14]. Finally, the absence
of risks for hypoglycaemia, although not studied specifically in
NICE-SUGAR, is questionable when the mortality rate of
patients who experienced hypoglycaemia was systematically
two to three times higher than in nonhypoglycaemic patients
(Figure 1). The effects of hypoglycaemia can be particularly
harmful in brain-injured patients [15,16].
With these uncertainties in mind, the only target for blood
glucose that can currently be recommended will probably be
in the intermediate range, even in the absence of direct
evidence. An intermediate level will probably allow safer
although effective glucose control [17].
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